Bladder Cancer Coverage from Every Angle
Advertisement
Advertisement

Recent News

Update From EV-103: Enfortumab Vedotin-ejfv Plus Pembrolizumab for Advanced Urothelial Carcinoma
Choice of Platinum in First Line Treatment of Advanced Urothelial Carcinoma in the Era of Second-Line Immunotherapy
A New Model Under Study to Predict Staging of Upper Tract Urothelial Cancer
Enfortumab Vedotin-ejfv Receives FDA Approval for Advanced Urothelial Carcinoma
Can Circulating Tumor Cells Predict Need for Neoadjuvant Chemotherapy in Bladder Cancer?
Bladder-Preserving Combined-Modality Therapy for Localized Muscle-Invasive Bladder Cancer
ASCO 2021: Chemotherapy Prior to Cystectomy for Older Patients With Muscle-Invasive Bladder Cancer
Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: Changing the Treatment Game
ASCO 2021: INDUCE-1 Trial of Feladilimab Plus Pembrolizumab in Urothelial Carcinoma
ASCO 2021: Neoadjuvant Therapy and Transurethral Resection of Bladder Cancer
ASCO 2021: Post Hoc Subgroup Analyses With Avelumab in Advanced Urothelial Carcinoma
ASCO 2021: 5-Year Update on Pembrolizumab for Advanced Urothelial Cancer
ASCO 2021: KEYNOTE-052 Survival Update on First-Line Pembrolizumab in Advanced Urothelial Cancer
ASCO 2021: Bladder-Sparing Combination Therapy Under Study in Muscle-Invasive Urothelial Cancer
Bladder Cancer Footprint? Fox Chase Researcher Awarded NIH Grant for Diagnostic Urine Test
Multimodal Imaging Strategy Under Study in Urothelial Cell Carcinoma
TROPHY-U-01 Supports Use of Sacituzumab Govitecan-hziy in Metastatic Urothelial Carcinoma
Lymphocyte-to-Monocyte Ratio: Prognostic Marker in Bladder Cancer?
Can Targeting APE1 and SSRP1 Improve Survival in Muscle-Invasive Bladder Cancer?
DNA Methyltransferase Inhibitor Under Study in Cisplatin-Resistant Urothelial Carcinoma
Update on Potential Biomarkers for Predicting Bladder Cancer Lymph Node Metastasis
First-Line Treatments in Metastatic Urothelial Cancer: Real-World Decision-Making
Priority Review Accepted by FDA for Nivolumab in Adjuvant Treatment of Muscle-Invasive Urothelial Cancer
Neoadjuvant Cabazitaxel Plus Cisplatin in Muscle-Invasive Bladder Cancer
Long-Term Outcomes and Costs of BCG Therapy for High-Risk Non–Muscle-Invasive Bladder Cancer
Metastatic Distribution of Urothelial Cancer: Differences Related to Age and Sex
Two sBLAs Accepted by FDA for Enfortumab Vedotin-ejfv in Urothelial Cancer
AACR 2021: Survival Outcomes by Treatment Response From IMvigor130 in Urothelial Cancer
Sacituzumab Govitecan-hziy Granted Accelerated Approval for Advanced Urothelial Carcinoma
Is Adjuvant Atezolizumab Safe and Effective in Muscle-Invasive Urothelial Cancer?
How Metabolic Factors May Influence Bladder Cancer Risk and Mortality
Potential Factors Linked to Patient Discontinuation of Therapy for Bladder Cancer
Adjuvant Durvalumab for Localized Urothelial Cancer
FDA Grants Two New Breakthrough Device Designations for MRD Testing
Radical Cystectomy for Progressive Versus de Novo Muscle-Invasive Bladder Cancer
Perioperative Chemotherapy Versus Surveillance in Urothelial Cancer: POUT Trial Update
Enfortumab Vedotin-ejfv: Antibody-Drug Conjugate for Advanced Urothelial Carcinoma
Racial Disparities and Access to Care in Bladder Cancer
Risk-Adapted Approaches to Managing Muscle-Invasive Bladder Cancer
Based on FDA Review, Manufacturer Withdraws Atezolizumab for Use in Bladder Cancer
GU Symposium 2021: Neoadjuvant Gemcitabine, Cisplatin, and Pembrolizumab in Bladder Cancer
GU Symposium 2021: Neoadjuvant Durvalumab Plus Chemotherapy in Muscle-Invasive Urothelial Carcinoma
Are There Racial Disparities in BCG Treatment of Non–Muscle Invasive Bladder Cancer?
Durvalumab Indication Withdrawn in Advanced Bladder Cancer in the United States
GU Symposium 2021: Novel IL-15 Superagonist for Non–Muscle-Invasive Bladder Cancer
Does Biologic Sex Influence Progression of Bladder Cancer After BCG Treatment?
GU Symposium 2021: Enfortumab Vedotin Versus Chemotherapy for Advanced Urothelial Carcinoma
GU Symposium 2021: Impact of Gender on Surgical Outcomes After Radical Cystectomy
GU Symposium 2021: Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Cancer
Proliposomal Paclitaxel in Non–Muscle Invasive Bladder Cancer: Study Supports Move to Phase IIb
Durvalumab-Based Combination Therapy in Non–Muscle Invasive Bladder Cancer


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.